As of August 27, LillyDirect made 2.5-mg and 5-mg single-dose vials of tirzepatide available to self-pay patients with an on-label electronic prescription. Lilly's announcement said the single ...

INDIANAPOLIS, Aug. 27, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced Zepbound ® (tirzepatide) 2.5 mg and 5 mg single-dose vials are available for self-pay for patients ...

Eli Lilly introduces 7.5 mg and 10 mg Zepbound vials for $499, ... (tirzepatide). Zepbound 2.5 mg and 5 mg single-dose vials are available for self-pay for patients with an on-label ...

Eli Lilly and Company LLY announced the launch of single-dose vials of its popular obesity drug, Zepbound (tirzepatide), to meet supply shortages in response to high demand.These 2.5 mg and 5 mg ...

The integration will streamline access to Lilly’s FDA-approved Zepbound® (tirzepatide) single-dose vials for WeightWatchers Clinic members with an on-label prescription from their clinician.

INDIANAPOLIS, Aug. 27, 2024 /PRNewswire/ -- Eli Lilly and Company today announced Zepbound ® (tirzepatide) 2.5 mg and 5 mg single-dose vials are available for self-pay for patients with an on ...

Eli Lilly and Company (NYSE: LLY) today announced Zepbound® (tirzepatide) 2.5 mg and 5 mg single-dose vials are available for self-pay for patients with an on-label prescription, significantly ...

--Eli Lilly and Company today announced Zepbound ® 2.5 mg and 5 mg single-dose vials are available for self-pay for patients with an on-label prescription, significantly expanding the supply of ...

Distributed through LillyDirect®'s self-pay channel, Zepbound single-dose vials are at least 50% less than the list price of all other incretin medicines for obesity ...